热门资讯> 正文
USANA Health预计2025财年净销售额将超过预期
2026-01-12 19:52
- USANA Health Sciences (USNA) currently anticipates fiscal year 2025 consolidated net sales of around $925M, ahead of its most recently issued guidance of ~$920M and consensus estimate of $919.85M.
- Net sales from USANA, the firm’s core nutritional business, are estimated to be around $777M; Hiya sales are expected to be ~$132M; and Rise Wellness sales are expected to be ~$16M.
- The company is issuing its initial net sales outlook for fiscal year 2026 in the range of $925M to $1B. This includes $720M to $765M from USANA, $140M to $155M from Hiya, and $65M to $80M from Rise Wellness.
- USNA +1.4% premarket to $20.14
- Source: Press Release
More on USANA Health Sciences
- USANA Health Sciences, Inc. 2025 Q3 - Results - Earnings Call Presentation
- USANA Health Sciences, Inc. (USNA) Q3 2025 Earnings Call Transcript
- Usana signals in-house Hiya manufacturing and cost reduction initiatives while expanding DTC strategy
- USANA Health Sciences Non-GAAP EPS of -$0.15 in-line, revenue of $213.67M in-line
- Seeking Alpha’s Quant Rating on USANA Health Sciences
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
